EUCTR2006-004374-27-DE进行中（未招募）不适用
Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent) - ProPATIent
Philipps-University0 个研究点开始时间: 2006年9月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •written informed consent
- •diagnosis of a generalized Myasthenia gravis (ICD10GM2006: G70.0)
- •positive Acetylcholine receptor antibodies
- •stable clinical course for at least 4 weeks before inclusion in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •contraindication for Mutagrip according to the Fachinformation
- •any vaccination in the last 9 months prior to study entry
- •serious or acute heart disease (e. g. uncontrolled cardiac dysrhythmias, angina pectoris, cardiomyopathy, congestive heart failure)
- •known allergy to chicken proteins, neomycine, formaldehyde, Octoxinol 9)
- •current infection or current pyrexia
- •history of cancer
- •severe adverse event in earlier vaccination
- •current participation in another clinical trail
研究者
相似试验
招募中
4 期
Prospective, randomized, double-blind, placebo-controlled, multicenter clinical investigation to determine the clinical performance and safety of Luvos® Healing Earth in patients with histamine-mediated recurrent digestive symptoms.T78.1T62K58K59Other adverse food reactions, not elsewhere classifiedToxic effect of other noxious substances eaten as foodOther functional intestinal disordersIrritable bowel syndromeDRKS00027333Heilerde-Gesellschaft Luvos Just GmbH % Co. KG114
进行中（未招募）
1 期
Cineole in acute non-purulent rhinosinusitisEUCTR2016-002743-41-DEEngelhard Arzneimittel GmbH & Co. KG250
进行中（未招募）
不适用
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disabilityChronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescentsMedDRA version: 18.0Level: PTClassification code 10039424Term: Salivary hypersecretionSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-004532-30-Outside-EU/EEAMerz Pharmaceuticals GmbH249
进行中（未招募）
1 期
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disabilityEUCTR2013-004532-30-HUMerz Pharmaceuticals GmbH249
进行中（未招募）
1 期
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injuryMedDRA version: 20.0Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852EUCTR2018-001639-35-ITMerz Pharmaceuticals GmbH600